✦ LIBER ✦

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

✍ Scribed by Joseph Eron Jr; Patrick Yeni; Joseph Gathe Jr; Vicente Estrada; Edwin DeJesus; Schlomo Staszewski; Philip Lackey; Christine Katlama; Benjamin Young; Linda Yau; Denise Sutherland-Phillips; Paul Wannamaker; Cindy Vavro; Lisa Patel; Jane Yeo; Mark Shaefer

Book ID: 117299679
Publisher: The Lancet
Year: 2006
Tongue: English
Weight: 106 KB
Volume: 368
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(06)69155-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dual therapy with lopinavir and ritonavi

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

✍ Cahn, Pedro; Andrade-Villanueva, Jaime; Arribas, José R; Gatell, José M; Lama, J 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 321 KB

Once-daily atazanavir/ritonavir versus t

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetcho 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 246 KB

Ritonavir-boosted lopinavir plus nucleos

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 311 KB

Durable efficacy of tipranavir-ritonavir

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

✍ Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlam 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 124 KB